Purpose To compare the prognostic significance of proliferation, as assessed by Ki67 expression, in breast cancer before and after neoadjuvant chemotherapy. Methods A retrospective search of a prospectively maintained clinical database was performed to identify patients treated with neoadjuvant chemotherapy at the Royal Marsden Hospital. The expression of Ki67 was assessed using immunohistochemistry in pre-therapy core-needle biopsy and post-therapy surgical excision specimens. The following factors were considered pre- and post-chemotherapy for their relationship with relapse-free and overall survival: age, menstrual status, T and N stage, pre-therapy operability, Ki67, ER, PgR, HER2, grade, histological subtype, vascular invasion, clinical response, chemotherapy regimen, type of surgery performed, adjuvant therapy, pathological tumour size and nodal involvement. Results In a matched cohort of 103 patients, on multivariate analysis of relapse-free survival, post-therapy Ki67 was the only significant independent prognostic factor. On multivariate analysis for overall survival, both pre- and excision Ki67 were significant independent predictors but the latter showed a stronger prognostic impact. The highest and lowest tertiles of excision Ki67 had different prognosis for both 5-year relapse-free (27% vs. 77%) and overall (39% and 93%) survival. In a cohort of 284 patients with only excision samples, post-therapy Ki67 was a significant independent prognostic factor on multivariate analysis. Conclusion Post-chemotherapy Ki67 is a strong predictor of outcome for patients not achieving a pathological complete response.
Breast cancer Neoadjuvant chemotherapy Post-therapy proliferation
This is a preview of subscription content, log in to check access.
de Azambuja E, Cardoso F, de Castro G Jr et al (2007) Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12, 155 patients. Br J Cancer 96:1504–1513. doi:10.1038/sj.bjc.6603756PubMedCrossRefGoogle Scholar
Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H (1984) Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133:1710–1715PubMedGoogle Scholar
Lee J, Im YH, Lee SH et al (2008) Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer. Cancer Chemother Pharmacol 61:569–577. doi:10.1007/s00280-007-0506-8PubMedCrossRefGoogle Scholar
Takada M, Kataoka A, Toi M et al (2004) A close association between alteration in growth kinetics by neoadjuvant chemotherapy and survival outcome in primary breast cancer. Int J Oncol 25:397–405PubMedGoogle Scholar
Billgren AM, Rutqvist LE, Tani E, Wilking N, Fornander T, Skoog L (1999) Proliferating fraction during neoadjuvant chemotherapy of primary breast cancer in relation to objective local response and relapse-free survival. Acta Oncol 38:597–601. doi:10.1080/028418699431186PubMedCrossRefGoogle Scholar
Osborne CR KL, Xie X-J, Ashfaq R, Bian A, Tripathy D (2006) Neoadjuvant chemotherapy for basal-like breast cancer cohort: clinical and pathological outcomes. Breast Cancer Res Treat 100(1):S53Google Scholar
Penault-Llorca F, Cayre A, Bouchet Mishellany F et al (2003) Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome. Int J Oncol 22:1319–1325PubMedGoogle Scholar
Faneyte IF, Schrama JG, Peterse JL, Remijnse PL, Rodenhuis S, van de Vijver MJ (2003) Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br J Cancer 88:406–412. doi:10.1038/sj.bjc.6600749PubMedCrossRefGoogle Scholar
Daidone MG, Veneroni S, Benini E et al (1999) Biological markers as indicators of response to primary and adjuvant chemotherapy in breast cancer. Int J Cancer 84:580–586. doi:10.1002/(SICI)1097-0215(19991222)84:6≤580::AID-IJC7≥3.0.CO;2-WGoogle Scholar
Bottini A, Berruti A, Bersiga A et al (1996) Effect of neoadjuvant chemotherapy on Ki67 labelling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumours. Anticancer Res 16:3105–3110PubMedGoogle Scholar
Honkoop AH, van Diest PJ, de Jong JS et al (1998) Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer 77:621–626PubMedGoogle Scholar
Vincent-Salomon A, Rousseau A, Jouve M et al (2004) Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy. Eur J Cancer 40:1502–1508. doi:10.1016/j.ejca.2004.03.014PubMedCrossRefGoogle Scholar